Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938431 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00938431 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 47 participants.
The verdict
NCT00938431, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and pharmacokinetics of LCM syrup in children ages from 1 month to 17 years with uncontrolled partial seizures when added to 1 to 3 other antiepileptic drugs (AEDs).
Interventions
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938431
The ClinicalTrials.gov registry entry for NCT00938431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lacosamide is the first listed.
NCT00938431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938431 about?
NCT00938431 is a clinical study titled "A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures". The purpose of this study was to evaluate the safety and pharmacokinetics of LCM syrup in children ages from 1 month to 17 years with uncontrolled partial seizures when added to 1 to 3 other antiepileptic drugs (AEDs).
What is the current status of trial NCT00938431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2009-11. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00938431?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00938431?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.